A Unique Technology Platform
Recce’s polymer-antibiotics are a new class of antibiotics targeted for human use, and have been developed to address the global crisis of superbugs.
About Recce
Recce Limited (ASX: RCE) a pre-clinical-stage pharmaceutical company engaged in the development of a new class of antibiotics for human use.
ASX:
RCE
$0
.000
Latest Announcements
Latest Presentation 18 Sep 17Investor Presentation |
Latest Broker Report 04 Apr 16Recce Antibiotic plus anti-cancer opportunities |
Learn More
Sign up for news and updates
Receive news and information direct to your inbox.